Serum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study

This publication has 29 references indexed in Scilit:

• Serum Half-Life of CA 125 during Early Chemotherapy as an Independent Prognostic Variable for Patients with Advanced Epithelial Ovarian Cancer: Results of a Multicentric Italian Study
  Gynecologic Oncology, 1995
• Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy
  Gynecologic Oncology, 1991
• Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.
  Journal of Clinical Oncology, 1991
• The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction
  American Journal of Obstetrics and Gynecology, 1990
• Prognostic factors in advanced epithelial ovarian cancer
  British Journal of Cancer, 1990
• The prognostic significance of the half‐life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma
  BJOG: An International Journal of Obstetrics and Gynaecology, 1989
• Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group.
  Journal of Clinical Oncology, 1989
• CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer
  American Journal of Obstetrics and Gynecology, 1989
• Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapy
  Gynecologic Oncology, 1988
• The clinical significance of pre-operative serum CA 125 in ovarian cancer
  BJOG: An International Journal of Obstetrics and Gynaecology, 1987